Company intelligence / Profile preview

Biochimpharm

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Biochimpharm’s phage-based products are used for the treatment and prevention of infections caused by resistant bacteria. The company has over-the-counter preparations with demonstrated safety and efficacy against major pathogens such as MRSA. Their products are distributed regionally and internationally; clinical results indicate effectiveness in combating antibiotic-resistant infections with no significant side effects reported

Therapeutic areas: Infectious Diseases
Modalities: Bacteriophages (phages)
Industry: Biotech

Drug pipeline

5 assets

Phagyo Spray

Unknown

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Biochimpharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biochimpharm.

Explore the full profile